Rethinking ADT: AI Biomarkers in Intermediate-Risk Prostate Cancer

Amar U. Kishan, MD, establishes why individualized ADT decision-making remains an unsolved problem in intermediate-risk prostate cancer.

Amar U. Kishan, MD, describes how the ArteraAI Prostate Test was built and validated, with particular attention to the RTOG 9408 data showing that more than 60% of intermediate-risk patients are biomarker-negative.

Amar U. Kishan, MD, walks through the design and results of the Markov model-based cost-effectiveness analysis, explaining what it means for the ArteraAI-guided strategy to dominate both comparators and why that finding held up across a wide range of sensitivity analyses.

Amar U. Kishan, MD, translates cost-effectiveness findings on the ArteraAI test into practical guidance for clinicians, payers, and health systems.

Amar U. Kishan, MD, explains how to translate the ArteraAI result into a meaningful patient conversation, reflects on what the cost-effectiveness data mean for the future of AI-guided precision oncology, and closes with a single takeaway for community urologists.